

10672 COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY

Table 1—Progesterone
(Survey Period - May 1972-September 1972)

MANUFACTURER	DECLARED POTENCY	NUMBER BATCHES SAMPLED AND ANALYZED	NUMBER DEFECTIVE SAMPLES
Progesterone Injection (Aqueous or oil):			
Bel-Mar Labs., Inc.	25.0 mg/ml	2	0
	50.0 mg/ml	1	0
	100.0 mg/ml	1	0
D-M Pharmaceuticals	50.0 mg/ml	1	0
Elkins-Sinn, Inc.	25.0 mg/ml	1	1 (a)
	50.0 mg/ml	1	1 (b)
Gotham Pharmaceutical Co., Inc.	50.0 mg/ml	1	0
Eli Lilly & Co.	50.0 mg/ml	2	0
	25.0 mg/ml	1	0
	50.0 mg/ml	1	0
Maury Biological Co., Inc.	50.0 mg/ml	1	0
Medical Chemicals Corp.	50.0 mg/ml	1	0
Myers-Carter Labs., Inc.	50.0 mg/ml	1	0
	100.0 mg/ml	1	0
Parke, Davis & Co.	25.0 mg/ml	1	— (c)
	50.0 mg/ml	1	0
Pasadena Research Labs., Inc.	50.0 mg/ml	1	0
	100.0 mg/ml	1	0
Schering Corporation	50.0 mg/ml	1	0
Titan Pharmaceutical Co., Inc.	50.0 mg/ml	1	0
TOTAL		20	2
Progesterone Injection Suspension:			
Elkins-Sinn, Inc.	25.0 mg/ml	1	0
	50.0 mg/ml	1	0
Hallmark Laboratories	25.0 mg/ml	1	0
	50.0 mg/ml	1	0
Maury Biological Co., Inc.	50.0 mg/ml	1	0
Medical Chemicals Corp.	25.0 mg/ml	2	0
	50.0 mg/ml	1	0
	100.0 mg/ml	1	0
Pasadena Research Labs., Inc.	25.0 mg/ml	1	0
Titan Pharmaceutical Co., Inc.	25.0 mg/ml	1	0
	50.0 mg/ml	1	0
TOTAL		12	0
Medroxyprogesterone Acetate Tablets:			
The Upjohn Co.	2.5 mg	1	0
	10.0 mg	3	0
TOTAL		4	0
Medroxyprogesterone Acetate Injection Sterile Suspension:			
The Upjohn Co.	50.0 mg/ml	3	0
	100.0 mg/ml	2	0
TOTAL		5	0
Hydroxyprogesterone Caproate Injection:			
E.R. Squibb & Sons Inc.	250.0 mg/ml	1	0
TOTAL		1	0
Dydrogesterone Tablets:			
Philip Roxane Labs., Inc.	5.0 mg	1	0
	10.0 mg	2	0
TOTAL		3	0
Ethisterone Tablets:			
Schering Corporation	10.0 mg	1	0
TOTAL		1	0
Norethindrone Tablets:			
Parke, Davis & Co.	5.0 mg	1	0
TOTAL		1	0
Norethindrone Acetate Tablets:			
Parke, Davis & Co.	5.0 mg	3	0
TOTAL		3	0
GRAND TOTAL		51	2

(a) Defective due to subpotency in five of six sub-samples. The average potency was 85.6 percent of declared for the sample. Removed from distribution channels by seizure action.

(b) Defective due to subpotency in each of six sub-samples. The average potency for the sample was 85.8 percent. Removed from distribution channels by seizure action.

(c) The result on this sample is not listed as defective because an apparent syringability problem interfered with the analysis. Because of this problem, the firm voluntarily recalled the batch.